Setmelanotide Acetate Drug Asset Due Diligence Report 2026

This Setmelanotide Acetate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Setmelanotide Acetate can convert its Synthetic peptide, Cyclic Peptide profile and MC4R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Setmelanotide Acetate (query alias: setmelanotide)
Modality / target	Synthetic peptide, Cyclic Peptide; MC4R; MC4R agonists
Highest global status	Approved
Originator	Ipsen SA
Active developers	Rhythm Pharmaceuticals, Inc., Ipsen SA, Rhythm Pharmaceuticals Netherlands BV

The MCP disease footprint includes Hypothalamic obesity, Bardet-Biedl Syndrome, Proopiomelanocortin Deficiency. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07674290	Phase 4	Recruiting	200	Percent change in BMI z-score
NCT06760546	Phase 3	Recruiting	39	Mean % change in BMI
NCT06772597	Phase 2	Active, not recruiting	18	Frequency and severity of adverse events (AEs)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Setmelanotide in Patients With Acquired Hypothalamic Obesity

Phase 3; n=143; evaluation: not stated. Reported fields: BMI(Least Squares Mean) = 3.32 Percent change (Standard Error, 1.984); BMI(Least Squares Mean): Least square mean difference = -19.83(95% CI, -24.55 to -15.10), P-Value = <0.0001; BMI(Least Squares Mean) = -16.51 Percent change (Standard Error, 1.401)

Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial

Phase 3; n=not disclosed; evaluation: Negative. Reported fields: BMI(ITT population,week 52): Difference (Mean) = -4.3, P-Value = 0.15; Difference (Mean) = -3.6, P-Value = 0.94; Difference (Mean) = -4.0, P-Value = 0.12; Difference (Mean) = -1.7, P-Value = 0.43 Not Met; BMI(ITT population,week 52): Difference (Mean) = -4.3, P-Value = 0.15; Difference (Mean) = -3.6, P-Value = 0.94; Difference (Mean) = -4.0, P-Value = 0.12; Difference (Mean) = -1.7, P-Value = 0.43 Not Met; BMI(ITT population,week 52): Difference (Mean) = -4.3, P-Value = 0.15; Difference (Mean) = -3.6, P-Value = 0.94; Difference (Mean) = -4.0, P-Value = 0.12; Difference (Mean) = -1.7, P-Value = 0.43 Not Met

Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome

Phase 2; n=18; evaluation: Positive. Reported fields: BMI = Six (6) of 8 patients who reached Month 3 of setmelanotide therapy achieved BMI reductions from baseline; three (3) of 5 patients who reached Month 6 of setmelanotide therapy achieved reductions in BMI, with two seeing deeper reductions versus Month 3 and one unchanged.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Setmelanotide Acetate addresses Hypothalamic obesity, Bardet-Biedl Syndrome, Proopiomelanocortin Deficiency. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide, Cyclic Peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2026-03-20	PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)	Approved	Financial terms not disclosed
2025-03-20	Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.	Approved	US$7.0M upfront; US$63.5M milestones; US$70.5M stated total
2021-07-22	Rhythm Pharmaceuticals and Medison Pharma Partner to Commercialize IMCIVREE™ (setmelanotide) in Israel	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Combinations of a potassium channel activator and an MC4r agonist and related methods of use”. The milestone feed surfaced a patent-application signal described as “Methods of treating obesity with an MC4r agonist”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO